Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Tumour angiogenesis: vascular growth and survival

View through CrossRef
Angiogenesis starts at the edge of a malignant epithelial tumour concurrently with tumour cell invasion and stromatogenesis, i.e. the formation of specific connective tissue stroma amenable to easy penetration by endothelial and tumour cells. However, as the tumour continues its growth, the edge becomes the inner tumour area, and a new invading tumour front is formed by the multiplying malignant cells which outflank the initial edge. This process, which repeats itself again and again, forms the “relay race” model of tumour vascular growth and regression. At the heart of the tumour unfavourable environmental conditions prevail – hypoxia, acidity, lack of nutrients, failure of waste removal, and apoptosis rather than proliferation. Blood vessels and tumour cells are greatly decreased, but do not vanish, as tumour cells are shifting to anaerobic glycolysis, and blood vessels are turning into anti‐apoptotic pathways – vascular survival ability (VSA). Thus, assessing vascular density (VD) by simply counting “hot spots” at the edge of a tumour, where conditions are most favourable, is futile; it may reflect tumour angiogenic activity (TAA), but is not representative of genuine tumour vasculature. By combining vessel counts at the invading tumour front with those of the inner tumour areas a complete picture of tumour VD can be achieved. The thus formed four patterns of vascularization, designated as “edvin” (edge vsinner tumour area), are: edvin 1: low TAA/low VSA; edvin 4: high TAA/high VSA; edvin 2: low TAA/high VSA; and edvin 3: high TAA/low VSA. It is expected that this scheme will prove useful in the field of chemoradiotherapy and anti‐angiogenic treatment.
Title: Tumour angiogenesis: vascular growth and survival
Description:
Angiogenesis starts at the edge of a malignant epithelial tumour concurrently with tumour cell invasion and stromatogenesis, i.
e.
the formation of specific connective tissue stroma amenable to easy penetration by endothelial and tumour cells.
However, as the tumour continues its growth, the edge becomes the inner tumour area, and a new invading tumour front is formed by the multiplying malignant cells which outflank the initial edge.
This process, which repeats itself again and again, forms the “relay race” model of tumour vascular growth and regression.
At the heart of the tumour unfavourable environmental conditions prevail – hypoxia, acidity, lack of nutrients, failure of waste removal, and apoptosis rather than proliferation.
Blood vessels and tumour cells are greatly decreased, but do not vanish, as tumour cells are shifting to anaerobic glycolysis, and blood vessels are turning into anti‐apoptotic pathways – vascular survival ability (VSA).
Thus, assessing vascular density (VD) by simply counting “hot spots” at the edge of a tumour, where conditions are most favourable, is futile; it may reflect tumour angiogenic activity (TAA), but is not representative of genuine tumour vasculature.
By combining vessel counts at the invading tumour front with those of the inner tumour areas a complete picture of tumour VD can be achieved.
The thus formed four patterns of vascularization, designated as “edvin” (edge vsinner tumour area), are: edvin 1: low TAA/low VSA; edvin 4: high TAA/high VSA; edvin 2: low TAA/high VSA; and edvin 3: high TAA/low VSA.
It is expected that this scheme will prove useful in the field of chemoradiotherapy and anti‐angiogenic treatment.

Related Results

Initiation of Acute Graft-Versus-Host Disease By Angiogenesis
Initiation of Acute Graft-Versus-Host Disease By Angiogenesis
Abstract Angiogenesis and inflammation are two closely related processes and inhibition of angiogenesis can ameliorate inflammatory diseases by reducing the recruitm...
Tumour Immunology
Tumour Immunology
Abstract Tumour immunology is central to our understanding of the mechanisms of both tumour rejection and tumour progression. Vir...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Tetrac as an anti-angiogenic agent in cancer
Tetrac as an anti-angiogenic agent in cancer
The thyroid hormones T3 and T4 have emerged as pro-angiogenic hormones with important implications for cancer management. Endogenous circulating hormone levels may help stimulate c...
Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma
Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma
Abstract Background The size of pancreatic ductal adenocarcinoma (PDAC) at diagnosis is an indicator of outcome. Previous studie...

Back to Top